ELDN Presents BESTOW Results
Eledon presents long-term extension phase 2 BESTOW results showing sustained higher kidney function and improved patient-reported outcomes with Tegoprubart compared with Tacrolimus
ELDN - Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus